Prof. Erik Biessen graduated at Groningen University in Biophysical Chemistry (1985), after which he joined the Division of Biopharmaceutics of Leiden University (Prof Dr Th.J.C. Van Berkel) as post-doctoral fellow.He was recruited for the prestigious Netherlands Heart Foundation funded Molecular Cardiology Program, to become Established Investigator in 2001. He received an innovational research incentive premium of the N.W.O in 2001 (VIDI/VICI precursor) amd acquired a second Established Investigatorship in 2004. Dr Biessen was appointed Professor in Therapeutic Gene Modulation at Leiden University in 2005. Since 2007 he is heading the Experimental Vascular Pathology group of CARIM (MUMC) and since 2015 he has a part-time affiliation at the Institute for Molecular cardiovascular research of RWTH Aachen. Dr Biessen is or has been board member of NHS-CVON ( 2010-2013), the Dutch Atherosclerosis Society (>2008), the ZonMW TOP grant committee, the Med6 Expert panel of FWO and the PhD assessment board of IWT (both Belgium). Furthermore he is scientific adviser of VantageView (St Louis, USA), a regular reviewer of Journal of Clinical Investigation, Circulation, Circulation Research, and Arteriosclerosis Thrombosis and Vascular Biology. He has authored over 200 papers in peer reviewed journals, has an HI of 57, and is holder of 10 patent applications.
Supervisor of project 8 - Dissecting the cross-interaction between vascular micro-calcification and inflammation: a human systems biology approach
